Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 5 |
| List of Tables | 5 | 1 |
| List of Figures | 6 | 1 |
| Introduction | 7 | 1 |
| Global Markets Direct Report Coverage | 7 | 1 |
| Aurora Kinase A (Serine/Threonine-Protein Kinase 15 or Aurora/IPL1-Related Kinase 1 or Aurora 2 or EC 2.7.11.1) Overview | 8 | 1 |
| Therapeutics Development | 9 | 4 |
| Aurora Kinase A (Serine/Threonine-Protein Kinase 15 or Aurora/IPL1-Related Kinase 1 or Aurora 2 or EC 2.7.11.1) Products under Development by Stage of Development | 9 | 1 |
| Aurora Kinase A (Serine/Threonine-Protein Kinase 15 or Aurora/IPL1-Related Kinase 1 or Aurora 2 or EC 2.7.11.1) Products under Development by Therapy Area | 10 | 1 |
| Aurora Kinase A (Serine/Threonine-Protein Kinase 15 or Aurora/IPL1-Related Kinase 1 or Aurora 2 or EC 2.7.11.1) Products under Development by Indication | 11 | 2 |
| Aurora Kinase A (Serine/Threonine-Protein Kinase 15 or Aurora/IPL1-Related Kinase 1 or Aurora 2 or EC 2.7.11.1) Pipeline Products Glance | 13 | 2 |
| Late Stage Products | 13 | 1 |
| Early Stage Products | 14 | 1 |
| Aurora Kinase A (Serine/Threonine-Protein Kinase 15 or Aurora/IPL1-Related Kinase 1 or Aurora 2 or EC 2.7.11.1) Products under Development by Companies | 15 | 4 |
| Aurora Kinase A (Serine/Threonine-Protein Kinase 15 or Aurora/IPL1-Related Kinase 1 or Aurora 2 or EC 2.7.11.1) Products under Development by Universities/Institutes | 19 | 2 |
| Aurora Kinase A (Serine/Threonine-Protein Kinase 15 or Aurora/IPL1-Related Kinase 1 or Aurora 2 or EC 2.7.11.1) Therapeutics Assessment | 21 | 5 |
| Assessment by Monotherapy/Combination Products | 21 | 1 |
| Assessment by Mechanism of Action | 22 | 1 |
| Assessment by Route of Administration | 23 | 2 |
| Assessment by Molecule Type | 25 | 1 |
| Aurora Kinase A (Serine/Threonine-Protein Kinase 15 or Aurora/IPL1-Related Kinase 1 or Aurora 2 or EC 2.7.11.1) Companies Involved in Therapeutics Development | 26 | 12 |
| AbbVie Inc. | 26 | 1 |
| Amgen Inc. | 27 | 1 |
| Astex Pharmaceuticals, Inc. | 28 | 1 |
| CASI Pharmaceuticals Inc. | 29 | 1 |
| Merck &Co., Inc. | 30 | 1 |
| Millennium Pharmaceuticals, Inc. | 31 | 1 |
| Sanofi | 32 | 1 |
| Sareum Holdings Plc | 33 | 1 |
| Sigma-Tau S.p.A. | 34 | 1 |
| Taiho Pharmaceutical Co., Ltd. | 35 | 1 |
| Vertex Pharmaceuticals Incorporated | 36 | 1 |
| Vichem Chemie Research Ltd. | 37 | 1 |
| Aurora Kinase A (Serine/Threonine-Protein Kinase 15 or Aurora/IPL1-Related Kinase 1 or Aurora 2 or EC 2.7.11.1) Drug Profiles | 38 | 30 |
| alisertib Drug Profile | 38 | 5 |
| AMG-900 Drug Profile | 43 | 2 |
| AT-9283 Drug Profile | 45 | 2 |
| danusertib Drug Profile | 47 | 1 |
| ENMD-2076 Drug Profile | 48 | 6 |
| ilorasertib Drug Profile | 54 | 2 |
| MK-8745 Drug Profile | 56 | 1 |
| SAR-156497 Drug Profile | 57 | 1 |
| SAR-3 Drug Profile | 58 | 1 |
| SAR-4 Drug Profile | 59 | 2 |
| Small Molecule to Inhibit Aurora A Kinase for Oncology Drug Profile | 61 | 1 |
| Small Molecule to Inhibit Aurora A Kinase for Oncology Drug Profile | 62 | 1 |
| Small Molecules to Inhibit Aurora A Kinase for Oncology Drug Profile | 63 | 1 |
| Small Molecules to Inhibit Aurora A/B Kinase for Oncology Drug Profile | 64 | 1 |
| ST-5589 Drug Profile | 65 | 1 |
| TAS-119 Drug Profile | 66 | 1 |
| VE-465 Drug Profile | 67 | 1 |
| Aurora Kinase A (Serine/Threonine-Protein Kinase 15 or Aurora/IPL1-Related Kinase 1 or Aurora 2 or EC 2.7.11.1) Dormant Projects | 68 | 9 |
| Aurora Kinase A (Serine/Threonine-Protein Kinase 15 or Aurora/IPL1-Related Kinase 1 or Aurora 2 or EC 2.7.11.1) Discontinued Products | 77 | 2 |
| Aurora Kinase A (Serine/Threonine-Protein Kinase 15 or Aurora/IPL1-Related Kinase 1 or Aurora 2 or EC 2.7.11.1) Featured News &Press Releases | 79 | 9 |
| Jun 01, 2016: CASI Pharmaceuticals Announces Poster Presentation At ASCO On ENMD-2076 In Patients With Ovarian Clear Cell Carcinoma | 79 | 1 |
| May 12, 2016: CASI Pharmaceuticals Receives Approval From CFDA To Conduct Phase 2 Clinical Trial With ENMD-2076 For Fibrolamellar Carcinoma (FLC) | 79 | 1 |
| Nov 08, 2015: Data On Anti-Tumor Activity Of ENMD-2076 In Triple Negative Breast Cancer Animal Models Presented In Poster Session At AACR-NCI-EORTC International Conference | 79 | 1 |
| Nov 05, 2015: Poster For ENMD-2076 Phase 2 Trial In Soft Tissue Sarcoma Presented At The 2015 Connective Tissue Oncology Society Annual Meeting | 80 | 1 |
| Nov 04, 2015: CASI Pharmaceuticals Announces First Patient Dosed In Phase 2 Trial For ENMD-2076 In Fibrolamellar Carcinoma | 81 | 1 |
| Oct 14, 2015: CASI Pharmaceuticals Receives EU Orphan Drug Designation For The Use Of ENMD-2076 To Treat Hepatocellular Carcinoma Including Fibrolamellar Carcinoma | 82 | 1 |
| Sep 15, 2015: US and European Patent Grants for Sareum's Aurora+FLT3 Kinase Inhibitors | 82 | 1 |
| Jun 04, 2015: CASI Files New Drug Clinical Trial Application With China FDA To Expand U.S. Development Of ENMD-2076 In Fibrolamellar Carcinoma | 82 | 1 |
| May 12, 2015: Takeda Announces Termination of Alisertib Phase 3 Trial in Relapsed or Refractory Peripheral T-cell Lymphoma | 83 | 1 |
| Mar 30, 2015: CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma | 83 | 1 |
| Mar 25, 2015: CASI Pharmaceuticals Announces Initiation Of A Phase 2 Trial With ENMD-2076 In Triple-Negative Breast Cancer In China | 84 | 1 |
| Feb 09, 2015: CASI Pharmaceuticals Announces Receipt Of Final Minutes From FDA Meeting Regarding Clinical And Regulatory Path Of ENMD-2076 For Fibrolamellar Carcinoma | 84 | 1 |
| Dec 17, 2014: CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma | 85 | 1 |
| Nov 12, 2014: CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Soft Tissue Sarcoma | 86 | 1 |
| Jul 21, 2014: CASI Pharmaceuticals Receives Approval From CFDA To Conduct Phase II Clinical Trial With ENMD-2076 For Triple-Negative Breast Cancer In China | 86 | 2 |
| Appendix | 88 | 2 |
| Methodology | 88 | 1 |
| Coverage | 88 | 1 |
| Secondary Research | 88 | 1 |
| Primary Research | 88 | 1 |
| Expert Panel Validation | 88 | 1 |
| Contact Us | 88 | 1 |
| Disclaimer | 89 | 1 |